BioSpace News Archive

Regeneron Pharmaceuticals, Inc. will host a conference call and simultaneous webcast to share updates on the company’s oncology portfolio in conjunction with the European Society for Medical Oncology Annual Congress on Monday, September 12, 2022.

LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company’s novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.41 per share.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial.

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Today, Health Canada authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine in children six months to four years of age.

As per Transparency Market Research, the global acute myeloid leukemia market (AML) therapeutics market will grow at a sturdy compound annual growth rate over the forecast period of 2020 to 2030 owing to growing incidence of AML.

With the rise in hospital acquired infections and rising awareness regarding the prevention of viruses the bio contamination market is expected to grow leaps and bounds during the forecast period.